Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from nicotiana
Reexamination Certificate
2005-06-21
2005-06-21
Meller, Michael (Department: 1654)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from nicotiana
C435S183000, C514S343000
Reexamination Certificate
active
06908631
ABSTRACT:
A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease the production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as “CYP2A6” for brevity) is predictive of an individual who: (1) has a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6 -mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analyzing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.
REFERENCES:
patent: 5653987 (1997-08-01), Modi
patent: 5760049 (1998-06-01), Viner
patent: 1803032 (1993-03-01), None
patent: WO9534679 (1995-12-01), None
Copy of International Search Report of PCT/CA98/01093, Aug. 1999.
Yamazaki, Hiroshi, et al., “Cytochrome P450 2E1 and 2A6 Enzymes as Major Cataysts for Metabolic Activation of N-nitrosodialkylamines and Tobacco-Related Nitrosamines in Human Liver Microsomes”.Carcinogenesis, vol. 13, No. 10, pp 1789-1794 (1992).
Kyerematen, Gabriel A., et al., “Metabolism of Nicotine by Hepatocytes,”Biochem. Pharmacol., vol. 40, No. 8, pp 1747-1756 (1990).
Foth, Heidi, et al., “Nicotine Metabolism in Isolated Perfused Lung and Liver of Phenobarbital- and Benzoflavone-Treated Rats,”Arch. Toxicol., vol. 65, No. 1, pp 68-72 (1991).
Tsujimoto, Akira, et al., “Potent Inhibitory Action of Pilocarpine on Hepatic Drub Metabolism,”Japan J. Pharmacol., vol. 22, No. 5, pp 736-739 (1972).
Nakajima, Miki, et al., “Charaterization of CYP2A6 Involved in 3'-Hydroxylation of Cotinine in Human Liver Microsomes”,J. Pharmacol. Exp. Therap., vol. 277, No. 2, pp 1010-1015 (1996).
Nakajima, Miki, et al., Role of Human Cytochrome P4502A6 in C-Oxidation of Nicotine,Drug Metabol. Dispos., vol. 24, No. 11 pp 1212-1217 (1996).
Tsuijimoto, Akira, et al., “A Study of the Nature of Pilocarpine Inhibition of Hepatic Drup-Metabolizing Enzymes,”Biochem. Parmacol, vol. 26, No. 21, pp 2072-2074 (1977).
Mays, et al., “Methoxsaien is a Potent Inhibitor of the Metabolism of Caffeine in Humans,”Clin. Pharmacol. Ther., 42(6):621-626 (1987).
Maenpaa, et al., “Metabolic Interactions of Methoxsaien and Coumarin in Humans and Mice,”Biochem. Pharmacol.48(7):1363-1369 (1994).
Benowitz, N.L., et al., “Deficient C-Oxidation of Nicotine,”Clinical Pharmacology and Therapeuticas, 57(5):590-594 (1995) (Abstract).
Sellers Edward Moncrieff
Tyndale Rachel F.
Hunton & Williams LLP
Meller Michael
Nicogen, Inc.
LandOfFree
Therapeutic and diagnostic methods dependent on CYP2A enzymes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic methods dependent on CYP2A enzymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic methods dependent on CYP2A enzymes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3498604